StockNews.AI
SRPT
StockNews.AI
112 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT

1. Pomerantz LLP is investigating Sarepta for potential securities fraud. 2. Investors are encouraged to contact the firm regarding claims. 3. Sarepta's stock dropped 27.44% following a death related to ELEVIDYS. 4. The investigation may impact Sarepta's officer and director accountability. 5. Sarepta's history of regulatory scrutiny adds to investor concerns.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop of 27.44% indicates severe market reaction post-disclosure. Historical incidents show that similar fraud allegations lead to long-term stock declines.

How important is it?

The article outlines serious allegations affecting Sarepta’s governance and financial stability. Historical parallels suggest that allegations of this nature typically have profound, lasting effects on stock prices.

Why Long Term?

Ongoing investigations can lead to prolonged uncertainty, affecting investor confidence. Previous class actions often result in lasting negative impacts on stock performance.

Related Companies

AVDLVRTX
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 18, 2025, Sarepta issued a press release disclosing the death of “a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS”, Sarepta’s Duchenne muscular dystrophy drug, “having suffered acute liver failure.” On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News